octohydroaminoacridine

Octohydroaminoacridine is a novel small molecule acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease. It is structurally related to tacrine but has been chemically modified to reduce hepatotoxicity, a common issue with earlier acridine derivatives. Octohydroaminoacridine demonstrates high central cholinomimetic specificity and a low butyrylcholinesterase to acetylcholinesterase (BuChE:AChE) binding ratio, indicating preferential inhibition of AChE in the central nervous system over peripheral tissues. Clinical trials have shown that it significantly improves cognitive function and behavior in patients with mild-to-moderate Alzheimer's disease, with effects being dose-dependent and generally well-tolerated without significant liver toxicity or serious adverse events[2][4][5][7]. The drug is being developed as an oral tablet formulation.

Brand names

Shen'eryang

Other names

octohydroaminoacridine succinate